These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 35705860)

  • 21. Clinical efficacy and in vitro neutralization capacity of monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 delta and omicron variants.
    Brehm TT; Pfefferle S; von Possel R; Karolyi M; Zoufaly A; Wichmann D; Kobbe R; Emmerich P; Nörz D; Aepfelbacher M; Schulze Zur Wiesch J; Addo MM; Schmiedel S; Lütgehetmann M
    J Med Virol; 2022 Oct; 94(10):5038-5043. PubMed ID: 35662058
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent antibodies against immune invasive SARS-CoV-2 Omicron subvariants.
    Wang L; Wang Y; Zhou H
    Int J Biol Macromol; 2023 Sep; 249():125997. PubMed ID: 37499711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance of SARS-CoV-2 Omicron BA.1 and BA.2 Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies.
    Zhou H; Dcosta BM; Landau NR; Tada T
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746806
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A SCID Mouse Model To Evaluate the Efficacy of Antivirals against SARS-CoV-2 Infection.
    Abdelnabi R; Foo CS; Kaptein SJF; Boudewijns R; Vangeel L; De Jonghe S; Jochmans D; Weynand B; Neyts J
    J Virol; 2022 Aug; 96(16):e0075822. PubMed ID: 35924921
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The spike receptor-binding motif G496S substitution determines the replication fitness of SARS-CoV-2 Omicron sublineage.
    Liang R; Ye ZW; Ong CP; Qin Z; Xie Y; Fan Y; Tang K; Poon VK; Chan CC; Yang X; Cao H; Wang K; Sun H; Hu B; Cai JP; Luo C; Chik KK; Chu H; Zheng Y; Yuen KY; Chan JF; Jin DY; Yuan S
    Emerg Microbes Infect; 2022 Dec; 11(1):2093-2101. PubMed ID: 35943779
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in the Omicron variant development.
    Vitiello A; Ferrara F; Auti AM; Di Domenico M; Boccellino M
    J Intern Med; 2022 Jul; 292(1):81-90. PubMed ID: 35289434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: Implications for immune escape and transmission.
    Shrestha LB; Foster C; Rawlinson W; Tedla N; Bull RA
    Rev Med Virol; 2022 Sep; 32(5):e2381. PubMed ID: 35856385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IMM-BCP-01, a patient-derived anti-SARS-CoV-2 antibody cocktail, is active across variants of concern including Omicron BA.1 and BA.2.
    Nikitin PA; DiMuzio JM; Dowling JP; Patel NB; Bingaman-Steele JL; Heimbach BC; Henriquez N; Nicolescu C; Polley A; Sikorski EL; Howanski RJ; Nath M; Shukla H; Scheaffer SM; Finn JP; Liang LF; Smith T; Storm N; McKay LGA; Johnson RI; Malsick LE; Honko AN; Griffiths A; Diamond MS; Sarma P; Geising DH; Morin MJ; Robinson MK
    Sci Immunol; 2022 Sep; 7(75):eabl9943. PubMed ID: 35771946
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model.
    Chiba S; Kiso M; Nakajima N; Iida S; Maemura T; Kuroda M; Sato Y; Ito M; Okuda M; Yamada S; Iwatsuki-Horimoto K; Watanabe T; Imai M; Armbrust T; Baric RS; Halfmann PJ; Suzuki T; Kawaoka Y
    mBio; 2021 Feb; 13(1):e0304421. PubMed ID: 35100870
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody evasion properties of SARS-CoV-2 Omicron sublineages.
    Iketani S; Liu L; Guo Y; Liu L; Chan JF; Huang Y; Wang M; Luo Y; Yu J; Chu H; Chik KK; Yuen TT; Yin MT; Sobieszczyk ME; Huang Y; Yuen KY; Wang HH; Sheng Z; Ho DD
    Nature; 2022 Apr; 604(7906):553-556. PubMed ID: 35240676
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum neutralization of SARS-CoV-2 Omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies.
    Bruel T; Hadjadj J; Maes P; Planas D; Seve A; Staropoli I; Guivel-Benhassine F; Porrot F; Bolland WH; Nguyen Y; Casadevall M; Charre C; Péré H; Veyer D; Prot M; Baidaliuk A; Cuypers L; Planchais C; Mouquet H; Baele G; Mouthon L; Hocqueloux L; Simon-Loriere E; André E; Terrier B; Prazuck T; Schwartz O
    Nat Med; 2022 Jun; 28(6):1297-1302. PubMed ID: 35322239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparing the Infectivity of Recent SARS-CoV-2 Omicron Sub-Variants in Syrian Hamsters.
    Abdelnabi R; Lassaunière R; Maes P; Weynand B; Neyts J
    Viruses; 2024 Jan; 16(1):. PubMed ID: 38257822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A potent neutralizing antibody provides protection against SARS-CoV-2 Omicron and Delta variants via nasal delivery.
    Zhang X; Zhang H; Li T; Chen S; Luo F; Zhou J; Zheng P; Song S; Wu Y; Jin T; Tang N; Jin A; Yang C; Cheng G; Gong R; Chiu S; Huang A
    Signal Transduct Target Ther; 2022 Aug; 7(1):301. PubMed ID: 36042204
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies.
    Jawad B; Adhikari P; Podgornik R; Ching WY
    Comput Biol Med; 2023 Dec; 167():107576. PubMed ID: 37871435
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary lesions following inoculation with the SARS-CoV-2 Omicron BA.1 (B.1.1.529) variant in Syrian golden hamsters.
    Rissmann M; Noack D; van Riel D; Schmitz KS; de Vries RD; van Run P; Lamers MM; Geurts van Kessel CH; Koopmans MPG; Fouchier RAM; Kuiken T; Haagmans BL; Rockx B
    Emerg Microbes Infect; 2022 Dec; 11(1):1778-1786. PubMed ID: 35787236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Booster vaccination with Ad26.COV2.S or an Omicron-adapted vaccine in pre-immune hamsters protects against Omicron BA.2.
    Swart M; van der Lubbe J; Schmit-Tillemans S; van Huizen E; Verspuij J; Gil AI; Choi Y; Daal C; Perkasa A; de Wilde A; Claassen E; de Jong R; Wiese KE; Cornelissen L; van Es M; van Heerden M; Kourkouta E; Tahiri I; Mulders M; Vreugdenhil J; Feddes-de Boer K; Muchene L; Tolboom J; Dekking L; Juraszek J; Vellinga J; Custers J; Bos R; Schuitemaker H; Wegmann F; Roozendaal R; Kuipers H; Zahn R
    NPJ Vaccines; 2023 Mar; 8(1):40. PubMed ID: 36927774
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.
    Abdelnabi R; Foo CS; De Jonghe S; Maes P; Weynand B; Neyts J
    J Infect Dis; 2021 Sep; 224(5):749-753. PubMed ID: 34244768
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Viral load decrease in SARS-CoV-2 BA.1 and BA.2 Omicron sublineages infection after treatment with monoclonal antibodies and direct antiviral agents.
    Mazzotta V; Cozzi Lepri A; Colavita F; Rosati S; Lalle E; Cimaglia C; Paulicelli J; Mastrorosa I; Vita S; Fabeni L; Vergori A; Maffongelli G; Carletti F; Lanini S; Caraffa E; Milozzi E; Libertone R; Piselli P; Girardi E; Garbuglia A; Vaia F; Maggi F; Nicastri E; Antinori A;
    J Med Virol; 2023 Jan; 95(1):e28186. PubMed ID: 36184918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model.
    Rosenke K; Okumura A; Lewis MC; Feldmann F; Meade-White K; Bohler WF; Griffin A; Rosenke R; Shaia C; Jarvis MA; Feldmann H
    JCI Insight; 2022 Jul; 7(13):. PubMed ID: 35579953
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intranasal or airborne transmission-mediated delivery of an attenuated SARS-CoV-2 protects Syrian hamsters against new variants.
    Stauft CB; Selvaraj P; D'Agnillo F; Meseda CA; Liu S; Pedro CL; Sangare K; Lien CZ; Weir JP; Starost MF; Wang TT
    Nat Commun; 2023 Jun; 14(1):3393. PubMed ID: 37296125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.